Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneu...
AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 ...
InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Cente...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreeme...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...
Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...
First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
"The A rating from MSCI is a significant recognition of our improvement in ESG performance," said Sherry Shao, Rotating CEO of GenScript. "We believe that ...
First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...
Aileron Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...
© 2025 Biopharma Boardroom. All Rights Reserved.
